Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 303,925
  • Shares Outstanding, K 148,256
  • Annual Sales, $ 163,910 K
  • Annual Income, $ -62,260 K
  • 60-Month Beta 2.37
  • Price/Sales 1.79
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade XERS with:

Options Overview Details

View History
  • Implied Volatility 26.41% ( -37.63%)
  • Historical Volatility 48.42%
  • IV Percentile 3%
  • IV Rank 2.11%
  • IV High 534.22% on 10/31/23
  • IV Low 15.49% on 05/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 122
  • Volume Avg (30-Day) 266
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 14,148
  • Open Int (30-Day) 13,104

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.11
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.69 +18.34%
on 04/26/24
2.07 -3.38%
on 05/17/24
+0.26 (+14.94%)
since 04/19/24
3-Month
1.69 +18.34%
on 04/26/24
3.26 -38.56%
on 03/01/24
-1.00 (-33.33%)
since 02/21/24
52-Week
1.46 +36.99%
on 11/15/23
3.26 -38.65%
on 02/15/24
-0.90 (-31.03%)
since 05/19/23

Most Recent Stories

More News
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 6.10 (-3.02%)
XERS : 2.00 (-2.44%)
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.00 (-2.44%)
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSolâ„¢ Formulations

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.00 (-2.44%)
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJectâ„¢

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 2.00 (-2.44%)
Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 2.00 (-2.44%)
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.00 (-2.44%)
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.00 (-2.44%)
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 2.00 (-2.44%)
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 2.00 (-2.44%)
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.00 (-2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 2.10
2nd Resistance Point 2.07
1st Resistance Point 2.04
Last Price 2.00
1st Support Level 1.98
2nd Support Level 1.95
3rd Support Level 1.92

See More

52-Week High 3.26
Fibonacci 61.8% 2.57
Fibonacci 50% 2.36
Fibonacci 38.2% 2.15
Last Price 2.00
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar